Viral hepatitis, caused by hepatitis viruses A through E, is a significant public health problem in India. An estimated 40 million people in India have chronic hepatitis B infection, constituting approximately 11% of the estimated global burden. Hepatitis C affects about 12 million patients in India. Both of these blood-borne infections have high risk of chronicity with progression to advanced liver disease and are associated with development of hepatocellular carcinoma, a type of liver cancer, underscoring the need for increased access to high quality, affordable and effective therapy in India.
Taj Pharmaceuticals India launched its HepcTaj Care division in April 2016 to respond to this public health concern and help meet the unmet medical needs of the patients in India who do not currently have access to critical medicines.